5-Fluorouracil (5-FU) and its prodrugs are the essential clinical drugs for colorectal cancer (CRC) treatment. However, the drug resistance of 5-FU has caused high mortality of CRC patients. Thus, it is urgent to develop reversal agents of 5-FU resistance. Sphingosine-1-phosphate receptor 2 (S1PR2) was proved to be a potential target for reversing 5-FU resistance, but the activity of known S1PR2 antagonists JTE-013 were weak in 5-FU-resistant cell lines. To develop more potent S1PR2 antagonists to treat 5-FU-resistant cancer, a series of JTE-013 derivatives were designed and synthesized. The most promising compound 40 could markedly reverse the resistance in 5-FU-resistant HCT116 cells and 5-FU-resistant SW620 cells via inhibiting the expression of dihydropyrimidine dehydrogenase (DPD). The key was that compound 40 with improved pharmacokinetic properties significantly increased the inhibitory rate of 5-FU in the SW620/5-FU cells xenograft model with no observable toxicity by inhibiting the expression of DPD in tumor and liver tissues. Altogether, these results suggest that compound 40 may be a promising drug candidate to reverse 5-FU resistance in the treatment of CRC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2021.113775 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nucleotide metabolism-associated drug resistance gene NDUFA4L2 promotes colon cancer progression and 5-FU resistance.
Sci Rep
January 2025
Department of Colorectal Surgery, Clinical Oncology School of Fujian Medical University, Fuzhou, 350004, Fujian, Fujian, P.R. China.
Article Synopsis
- Chemotherapy significantly improves prognosis for colorectal cancer patients, but resistance to drugs like 5-Fluorouracil (5-FU) is a growing problem.
- Research identified that nucleotide metabolism may play a key role in both cancer progression and drug resistance, leading to the development of a risk score model to predict patient outcomes.
- The study found that the gene NDUFA4L2 enhances colon cancer cell growth and movement, contributing to resistance against 5-FU, highlighting its potential as a target for improving treatment strategies.
TYMS Enhances Colorectal Cell Antioxidant Capacity Via the KEAP1-NRF2 Pathway to Resist Ferroptosis.
J Cancer
January 2025
The Colorectal and Anal Surgery Department of Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan, China.
Thymidylate synthase (TYMS) is a key regulatory enzyme in DNA synthesis. We identified the biological effect and molecular mechanisms of TYMS in colorectal cancer (CRC). We employed western blot and immunohistochemistry for the assessment of TYMS expression in CRC samples.
View Article and Find Full Text PDFInhibiting autophagy selectively prunes dysfunctional tumor vessels and optimizes the tumor immune microenvironment.
Theranostics
January 2025
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan Province, People's Republic of China.
Dysfunctional tumor vasculature, hypoxia, and an immunosuppressive microenvironment are significant barriers to effective cancer therapy. Autophagy, which is critical for maintaining cellular homeostasis and apoptosis resistance, is primarily triggered by hypoxia and nutrient deprivation, conditions prevalent in dysfunctional tumor vessels due to poor circulation. However, the role of autophagy in dysfunctional tumor endothelial cells and its impact on treatment and the tumor microenvironment (TME) remain poorly understood.
View Article and Find Full Text PDFGPLD1+ cancer stem cells contribute to chemotherapy resistance and tumor relapse in intestinal cancer.
J Biochem
January 2025
Laboratory of Anticancer Strategies, Advanced Research Initiative, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.
Article Synopsis
- Cancer stem cells (CSCs) are crucial in cancer growth and resistance, and recent research has identified GPLD1 as a marker for slowly cycling CSCs using a mouse intestinal cancer model.
- Inhibiting GPLD1, particularly combined with the chemotherapy drug 5-fluorouracil, significantly reduces cancer cell viability and prevents tumor regrowth in organoids.
- The study also reveals the role of GPLD1 in activating Wnt signaling and promoting epithelial-mesenchymal transition (EMT) through the cleavage of serine protease 8 (PRSS8), indicating that targeting GPLD1 could be a promising new treatment approach for colorectal cancer.
A 3D bioprinted potential colorectal tumor model based on decellularized matrix/gelatin methacryloyl/nanoclay/sodium alginate hydrogel.
Int J Biol Macromol
December 2024
Cancer Hospital of Dalian University of Technology, State Key Laboratory of Fine Chemicals, Dalian R&D Center for Stem Cell and Tissue Engineering, Dalian University of Technology, Dalian 116024, China. Electronic address:
Colorectal cancer (CRC) is now the third most common cancer worldwide. However, the development cycle for anticancer drugs is lengthy and the failure rate is high, highlighting the urgent need for new tumor models for CRC-related research. The decellular matrix (dECM) offers numerous cell adhesion sites, proteoglycan and cytokines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!